Navigation Links
Challenge the Performance of Your Hot-Start PCRs,,,with FastStart Taq DNA Polymerase and,,,the Novel FastStart High Fidelity PCR System

The FastStart Taq DNA Polymerase

FastStart Taq DNA Polymerase, a chemically modified version of Taq DNA Polymerase for hot start PCR, was introduced in 2000. Based on the feedback from many customers, FastStart Taq DNA Polymerase has proven to be: The most robust enzyme preparation currently available
Even the most challenging PCRs are no longer a problem. In applications where other polymerases stop working, FastStart Taq DNA Polymerase gives effective results (Figures 1, 2, and 3).

The most versatile enzyme preparation currently available

FastStart Taq DNA Polymerase is also the enzyme of choice for real-time quantitative PCR, e.g., as applied on the LightCycler Instrument. It is also included in most LightCycler System reagent kits.

The FastStart High Fidelity PCR System
The novel FastStart High Fidelity PCR System contains the new FastStart High Fidelity Enzyme Blend: a new blend of FastStart Taq DNA Polymerase and a thermostable proofreading protein that mediates proofreading activity, but has no polymerase activity itself.
This enzyme blend is inactive at temperatures below 75C and does not elongate nonspecific primer-template hybrids that may form during PCR setup. After activation via a two-minute incubation step at 95C, the processivity of FastStart Taq DNA Polymerase, and the ability of the proofreading protein to recognize and excise incorrectly incorporated nucleotides, combine
'"/>

Source:


Page: All 1 2

Related biology technology :

1. The Best Enzyme for the Toughest PCR Challenges Improved with New Hot-Start Feature
2. Novel PCR Enhancing Factor Improves Performance of Pfu DNA Polymerase
3. Comparing Fidelity and Performance of Proofreading PCR Enzymes
4. PCR Performance Comparisons Between pfuturbo and Taq DNA Polymerases
5. pfuturbo DNA Polymerase: A High-Performance, High-Fidelity Enzyme Ideal for PCR Cloning
6. Performance Comparisons of Commercial RT-PCR Systems
7. Restriction Endonucleases Undergo Rigorous QC Testing to Ensure Optimal Performance
8. Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR Performance
9. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
10. Highly Sensitive microRNA Array Performance
11. High Throughput RNA Isolation for High Performance Microarray Analysis

Post Your Comments:
(Date:11/6/2009)...Intarcia Therapeutics, Inc. delivered two presenta...s delivery of exenatide) program for the treatment...echnology Meeting in San Francisco, CA: ,, (Log...FTU126LOGO ) ,, Continuous Subcutaneous Deliv...e, HbA1c and Reduces Weight in a 28-day Phase 1b S...
(Date:11/5/2009)...rstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) today an...r ended September 30, 2009. GenVec reported a net ...ee months ended September 30, 2009 compared to a n...omparable quarter of 2008. For the nine months end... million ($0.15 per share), compared to a net loss...
(Date:11/5/2009)... -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), a... CEO of Imagenetix, will be presenting the Company...Thursday, December 3rd, at 10:30 AM PST at the Lux..., LD MICRO is a by-invitation only newsletter firm...the micro-cap space. Since 2002, the firm has publ...
(Date:11/5/2009)...l/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO...r ended September 30, 2009. The Company,s financia... ,, Third Quarter 2009 ,, The Company repo... the third quarter of 2009 as compared to a net lo...arter of 2008. ,, Net sales were $5.0 million ...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...by EBS is without merit and part of its overall st...iness without getting shareholder, approval and t...nding to PSC., -...o pursue its business, strategy of obtaining FDA a... and seeking additional federal and third party...
...evenues increased 38% to $42.3 million Full...n, SHANGHAI, China, July 10 /Xinhua-PRNewswire-Fi...d: CHBT) ("China-Biotics", "the,Company"), a leadi...search, development, marketing and distribution of... results for the fourth quarter and fiscal,year en...
...nce, July 10 , - 1st Half-Year Sales Up 16%, - ...reater than or equal,to)12%, EUR millions .../07 EURM %Sales EURM %S... change chang... 13 26.8 71 15 Other EU countries (2) ...
Other Biology Technology:Protein Sciences Responds to Emergent BioSolutions Lawsuit 2Protein Sciences Responds to Emergent BioSolutions Lawsuit 3Protein Sciences Responds to Emergent BioSolutions Lawsuit 4Protein Sciences Responds to Emergent BioSolutions Lawsuit 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 4China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 6China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 7China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 8China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 9China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 10China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 11China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 12China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 13Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth 2
(Date:11/4/2009)...dhood obesity in the United States is reaching epi...vertising on daytime and prime time television dev...ns about the role television plays in obesity, a s...l of Nutrition Education and Behavior examines ho...rge contributor to the problem. , Researchers at...
(Date:11/4/2009)...has received more than $10 million in research gra...ral stimulus program, bringing thetotal amount of ... million. Thirty-three projects achieved stimulus...eather. , "The university has thoughtfully under...holarly excellence to federal agency priorities. ...
(Date:11/4/2009)...Newswire/ -- DigitalPersona, Inc., a leader in fin...day announced that WAND Corporation, a leading sup...rvice restaurants, has integrated DigitalPersona t...olutions. WAND,s quick-service customers can now u...ability and deter unauthorized manager overrides. ...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 3DaVitas Patient Centric Modalities Offer Students with Kidney Disease More Choices 56685 1DaVitas Patient Centric Modalities Offer Students with Kidney Disease More Choices 56685 2Childrens Hospital receives federal contract to study antibiotic use in children with UTIs 56680 1Medicine wheel model for nutrition shows promise for control of type 2 diabetes 9854 1Medicine wheel model for nutrition shows promise for control of type 2 diabetes 9854 2
...mal model for the painful nerve condition known as...at it, according to Duke University bioengineers a... but rather a diverse range of symptoms, such as n...adiating leg pain or difficulty in controlling the...ng, of any of the five nerve roots that combine to...
...at Scripps Institution of Oceanography at UC San D...tures below the cobalt blue waters of Lake Tahoe o...ripps research team offer a more comprehensive ana...ion, which suggest a magnitude-7 earthquake occurs... the largest fault in the basin, West Tahoe, appea...
...en using a growing volume of genetic data to debat...to the New World in one wave or successive waves, ... of different populations. , Now, after painstaki...f modern-day Native American and Eurasian groups, ...put the matter to rest: Virtually without exceptio...
Other Biology News:Limping rat provides sciatica insights 2Scripps studies offer new picture of Lake Tahoe's earthquake potential 2Native Americans descended from a single ancestral group, DNA study confirms 2Native Americans descended from a single ancestral group, DNA study confirms 3
... V is a fully integrated system for fluorescent b...that deliver excellent quality microarray images. ...er that is based on patented confocal laser imagin...spatial resolution. The DNAscope V images two fluo...
Rabbit Anti-Ca2+ Channel Ca gamma 2 Polyclonal Antibody, Unconjugated from BD Biosciences Pharmingen
Rabbit Anti-Nuclear Receptor Coactivator 2 (NCOA2) Polyclonal Antibody, Agarose Conjugated from Novus Biologicals
Anti-Monocarboxylate Transporter 2 (MCT2) Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: